Essex Investment Management’s AC Immune ACIU Stock Holding History

Essex Investment Management’s Portfolio ACIU Stock Details ACIU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-37,968	Closed	-$359K	–	481
2018 Q4	$359K	Buy	+37,968	New	+$359K	0.06%	272

Other funds holding ACIU

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Essex Investment Management's ACIU Position: Q1 2019 in Review

Essex Investment Management sold out of AC Immune (ACIU) in Q1 2019, closing a stake of 37,968 shares — an estimated $359K sold.

Essex Investment Management first reported a position in ACIU in Q4 2018 and held it in 1 quarter. The position peaked at $359K in Q4 2018. 41 funds tracked by Wall St. Rank hold ACIU as of Q1 2019.

Essex Investment Management reported no remaining AC Immune position as of Q1 2019 after selling out during the quarter.
Essex Investment Management sold 37,968 AC Immune shares in Q1 2019, an estimated $359K.
Essex Investment Management first reported a position in AC Immune in Q4 2018 and held it in 1 quarter.
Essex Investment Management's AC Immune position peaked at $359K in Q4 2018.
41 funds tracked by Wall St. Rank held AC Immune as of Q1 2019.

Based on Essex Investment Management's 13F filing for Q1 2019, filed 15 May 2019.